1月7日 - ** 制药商 Ionis Pharmaceuticals IONS.O 股价上涨 4.8% 至 85.41 美元，创下近七年新高
** 该公司的合作伙伴葛兰素史克公司GSK.L宣布， (link)，乙型肝炎治疗的后期试验结果呈阳性。
** 从 IONS 公司获得许可的这种药物可以阻断乙型肝炎病毒的复制，减少与感染有关的蛋白质的生成
** 葛兰素史克公司表示，这种药物的年销售额将超过 20 亿英镑(27.0 亿美元)
** 葛兰素史克公司计划在 2026 年第一季度向监管部门申请批准
** IONS 的股价在 2025 年翻了一番多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.